English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/183560
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Bedaquiline, anti MDR-TB drug, is efficiently nanoencapsulated

AuthorsMatteis, Laura de; Jary, Dorothée; Lucía, Ainhoa; Serrano-Sevilla, Inés; García-Embid, Sonia; Navarro, Fabrice; Fuente, Jesús M. de la; Aínsa, José A.
Issue Date2017
CitationVIII National Conference BIFI (2017)
AbstractAntibiotic resistance in Mycobacterium tuberculosis is a declared global health emergency, and rising cases of MDR-TB, and XDR-TB are making increasingly difficult to treat tuberculosis nowadays. After 50 years without any new drug for TB, in 2012 the FDA approved the use of bedaquiline, the first drug designed specifically to treat MDR-TB. It is very effective but shows serious side effects, and consequently, it can only be prescribed when no other treatment options are available. Novel drug delivery systems based on nanocarriers are a promising strategy to overcome current therapeutic challenges due to their unique physicochemical properties, like small size or high surface to volume ratio. Nanocarriers improve the aqueous solubility of poorly soluble drugs, protects the drugs, and allow a controlled release of the medication. Additionally they can be modified to control their biodistribution allowing selective transport to the sites of infection. The development of effective and safe nanotherapy methods is particularly relevant in the treatment of MDR-TB, as it requires very long treatments with highly toxic drugs. In this sense the nanoencapsulation of bedaquiline is of special interest. In this work, chitosan based nanocapsules and Lipid NanoParticles, based on the Lipidots® technology, have been synthesized and optimized for the encapsulation of bedaquiline. upon quantification of drug loading efficiency, improvement of the drug payload, and nanoparticles stability amelioration in storage conditions. For the best candidates, drug release has been determined in biological media for in vitro assays. The antimycobacterial activity has finally been evaluated to confirm that the drug is still active after encapsulation, and, their cytotoxicity has been assayed in different cell lines.
DescriptionResumen del trabajo presentado a la VIII National Conference BIFI, celebrada en el Edificio I+D Campus "Río Ebro" de la Universidad de Zaragoza, del 31 de enero al 2 de febrero de 2017.
URIhttp://hdl.handle.net/10261/183560
Appears in Collections:(ICMA) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.